Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > BUSINESS
BUSINESS
- AnGes Sales Up 10.5% but Logs 1,409 Million Yen Net Loss in 2013
February 12, 2014
- Ethical Drug Sales Up 4.7% in December: Crecon Report
February 12, 2014
- Asahi Kasei Pharma Completes 2nd Manufacturing Facility at Nagoya Pharmaceuticals Plant
February 12, 2014
- Novartis Appoints Former Tokyo High Court Judge to Head Independent Commission to Investigate Scandal Over SIGN Study
February 10, 2014
- Transdermal Parkinson’s Disease Treatment Ropinirole Shows Significant Difference in PII Study: Hisamitsu
February 10, 2014
- Mitsubishi Chemical to Set Up New Healthcare Firm
February 7, 2014
- MTPC Appoints Development Division Manager as New Representative Director
February 7, 2014
- Takeda CFO Says Midterm Strategy Not Affected by Halt of TAK-875 Trials
February 7, 2014
- Astellas to Bring Global Development, Regulatory Affairs Functions Under Control of Chief Medical Officer
February 7, 2014
- JCR, GSK Ink Research Support Agreement to Establish New Technology
February 6, 2014
- Kyorin Pushes Easy to Use Inhaler Flutiform, Aims for Higher Market Penetration
February 6, 2014
- Fujifilm Pharma Gets Japan Distribution Rights for Sosei’s Oropharyngeal Candidiasis Drug
February 6, 2014
- Kyowa Kirin Begins Japan PIII Trial of ARQ 197 for Hepatocellular Cancer
February 6, 2014
- Eisai to File Lenvatinib for Approval in Japan, US, Europe as Early as June
February 6, 2014
- NDA for Lorcaserin Expected to Be Filed in Japan in FY2016 or Later: Eisai
February 5, 2014
- 396 Eisai Workers Take Voluntary Retirement, FY2013 Net Profit Forecast Revised Downward
February 5, 2014
- DSP Expands Collaboration with Edison for Development of Mitochondrial Disease Treatment
February 5, 2014
- Kyowa Kirin to Integrate Research and Development Divisions
February 4, 2014
- Drug Wholesalers Laud Medical Fee Cuts to Fix Lengthy Haggling, Pharmacy Chains Vexed by Rule
February 4, 2014
- Kyowa Kirin Drug Prices Expected to Slip by 7% Due to NHI Price Revision
February 4, 2014
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…